Safety, Efficacy, and Pharmacokinetic Analysis of Glecaprevir/Pibrentasvir in Pediatric Patients With Genotypes 1–6 Chronic Hepatitis C Virus (HCV) Infection: Part 2 of the DORA Study

Jonas, M.; Rhee, S; Kelly, D; Del Valle Segarra, A; Feiterna-Sperling, C; Gilmour, S; Gonzalez-Peralta, RP; Hierro, L; Leung, D.H.; Ling, S.C.; Lobzin, Y; Lobritto, S; Narkewicz, M.R; Sabharwal, V; Wen, J; Kei Lon, H; Marcinak, J.; Topp, A; Tripathi, R; Sokal, Etienne

Safety, Efficacy, and Pharmacokinetic Analysis of Glecaprevir/Pibrentasvir in Pediatric Patients With Genotypes 1–6 Chronic Hepatitis C Virus (HCV) Infection: Part 2 of the DORA Study

Jonas, M.

;

Rhee, S

;

Kelly, D

;

Del Valle Segarra, A

;

Sokal, Etienne

;et.al.

(2020) The Liver Meeting Digital Experience - AASLD — Location: WEBINAR (13.November.2020)

Files

Jonas_DORApart2_AASLD2020_LB_LP2.pdf

Open Access
Adobe PDF
258.37 KB

Download

Details

Authors

Jonas, M.
Author
Rhee, S
Author
Kelly, D
Author
Del Valle Segarra, A
Author
Sokal, EtienneUCLouvain
Author

Affiliations

Citations

APA
Chicago
FWB

Jonas, M., Rhee, S., Kelly, D., Del Valle Segarra, A., Feiterna-Sperling, C., Gilmour, S., Gonzalez-Peralta, R., Hierro, L., Leung, D. H., Ling, S. C., Lobzin, Y., Lobritto, S., Narkewicz, M. R., Sabharwal, V., Wen, J., Kei Lon, H., Marcinak, J., Topp, A., Tripathi, R., & Sokal, E. (2020). Safety, Efficacy, and Pharmacokinetic Analysis of Glecaprevir/Pibrentasvir in Pediatric Patients With Genotypes 1–6 Chronic Hepatitis C Virus (HCV) Infection: Part 2 of the DORA Study. Journal of Hepatology. Supplement, 72. https://hdl.handle.net/2078.5/117385 (Original work published 2020)